Tela Bio, INC Schedule 13G passive stakes

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.8% of Tela Bio, Inc.'s Class A Common Stock as of June 30, 2026.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.8% of TELA BIO, Inc.'s Class A Common Stock as of June 30, 2026.

Laurence W. Lytton has disclosed beneficial ownership of 2,442,341 shares, representing 5.5% of the outstanding common stock of TELA Bio, Inc., as of March 31, 2026.

EW Healthcare Partners and its affiliates have increased their beneficial ownership in TELA Bio, Inc. to an aggregate of 17.32% of common stock following a recent direct offering.

Laurence W. Lytton has reported a 7.2% beneficial ownership stake in TELA Bio, Inc., holding 2,865,305 shares of common stock as of September 30, 2025.

GROW Funds, LLC has filed an amendment to its Schedule 13G, indicating its beneficial ownership in TELA Bio, Inc. common shares has fallen to 5% or less.

Laurence W. Lytton has increased his beneficial ownership in TELA Bio, Inc. to 8.5% of the common stock outstanding.

A group of investment entities and individuals, led by North Run Capital, LP, has filed an amended Schedule 13G disclosing a collective beneficial ownership of 9.3% of TELA Bio, Inc.'s common stock.

North Run Capital, LP and its affiliated entities, including North Run Advisors, LLC and North Run Due North Partners, LP, along with key individuals, have disclosed a passive 5% beneficial ownership stake in TELA Bio, Inc., totaling 1,982,489 shares of common stock.

AIGH Capital Management LLC and Orin Hirschman have filed an amended Schedule 13G, disclosing a beneficial ownership of 3.6% of TELA Bio, Inc.'s common stock as of March 31, 2025.

Nantahala Capital Management, along with its managers Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 12.9% in TELA Bio, Inc., holding over 5.1 million shares.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% of TELA Bio, Inc.'s common stock as of December 31, 2024.

Stonepine Capital Management, LLC and its affiliates have disclosed a 6.0% beneficial ownership stake in TELA Bio, Inc. as of December 31, 2024.

SilverArc Capital Management, LLC and Devesh S. Gandhi have disclosed a passive beneficial ownership of 7.78% of TELA Bio, Inc.'s Class A Common Stock as of December 31, 2024.

AIGH Capital Management LLC and its affiliates, including Orin Hirschman, have disclosed a 6.8% beneficial ownership stake in TELA Bio, Inc.'s common stock as of December 31, 2024, through an amended Schedule 13G filing.